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Purpose: Aniridia is phenotyically and genetically heterogeneous. This study is to summarize the phenotypes and identify
the genetic defect responsible for aniridia and congenital progressive cataract in a three generation Chinese family.
Methods: A detailed family history and clinical data from patients were collected by ophthalmologic examination,
including  visual  acuity,  slit-lamp  examination,  tonometer,  keratometry,  corneal  topography,  optical  coherence
tomography, and ultrasonic A/B scan. All exons and flanking intronic sequences of the paired box 6 (PAX6) gene were
amplified by polymerase chain reaction (PCR) and screened for mutation by direct DNA sequencing. Structure and
function of the mutant PAX6 were analyzed by bioinformatics analysis.
Results: All the six patients shared common manifestations of complete aniridia, congenital cataract and thickened cornea,
and broad phenotypic variability was observed in nystagmus, ptosis, strabismus, glaucoma, corneal pannus, corneal
curvature, corneal vascularization, cataract subtype, ectopia lentis, axial length, and optic disc anomalies. Sequencing of
the candidate gene detected a heterozygous c.307C>T transition in the coding region of PAX6, resulting in the substitution
of a highly conserved arginine codon for a termination codon (p.R103X). The p.P103X mutation co-segregated with the
affected individuals in the family. The change was supposed to cause structural and functional changes based on
computational analysis.
Conclusions: We identified a recurrent PAX6 c.307C>T mutation in an aniridia and congenital progressive cataract family,
and summarized the variable phenotypes among the patients, which expanded the phenotypic spectrum of aniridia in a
different ethnic background.
Aniridia (OMIM 106210) is a rare bilateral panocular
disorder characterized by complete absence or partial absence
of the iris [1]. It is associated with a range of other ocular
abnormalities  including  aniridia-associated  keratopathy
(AAK), ectopia lentis, cataract, glaucoma, nystagmus, foveal
hypoplasia,  and  optic  nerve  hypoplasia,  which  results  in
vision loss [2,3]. About two thirds of the cases of congenital
aniridia are inherited as an autosomal dominant trait with high
penetrance and variable expressivity [4,5]. The aniridia gene
has been mapped on chromosome 11p13 by linkage analysis
and positional cloning. The pair box gene 6 (PAX6) located at
11p13 is confirmed to be the major gene associated with
aniridia [6-9].
Congenital cataract (OMIM 604307) is an opacification
of  the  eye  lens  resulting  in  visual  impairment  or  even
blindness during infancy or early childhood [10]. According
to the Human PAX6 Allellic Variant Database [11], over 60
PAX6 mutations have been reported to be associated with
aniridia  accompanied  with  congenital  cataract.  However,
identified  mutations  are  located  throughout  the  length  of
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PAX6  with  limited  clear  evidence  of  genotype-phenotype
correlation.
In  this  study,  we  present  the  clinical  and  molecular
genetic evaluations performed on a three generation aniridia
and congenital progressive cataract family of Chinese origin.
METHODS
Clinical  data  evaluation:  A  family  having  autosomal
dominant aniridia and congenital progressive cataract in three
successive generations was recruited in the Eye Center of
Second  Affiliated  Hospital,  Medical  College  of  Zhejiang
University, Hangzhou, China. The study was performed in
accordance with the Declaration of Helsinki and approved by
the  Zhejiang  Institutional  Review  Board,  and  informed
consent was obtained from all participants. The diagnosis was
confirmed by ophthalmologic examinations, including visual
acuity,  slit-lamp  examination,  tonometer,  keratometry,
corneal topography, optical coherence tomography, ultrasonic
A/B  scan  visual  acuity,  slit-lamp  examination,  corneal
topography, optical coherence tomography, or a history of
cataract extraction. Ocular photographs were taken by slit-
lamp photography without pupil dilation. Twelve individuals
(6 affected and 6 unaffected) from the family participated in
the study (Figure 1). One hundred unrelated subjects were
recruited as controls.
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465Genomic DNA preparation and molecular analysis: Blood
specimens (5 ml) from all the family members were collected
in EDTA. Genomic DNA was isolated as previously described
[12]. Briefly, 200 μl of the blood was incubated at 56 °C for
1 h in 200 μl of lysis buffer (provided in the kit) containing
25 ml of proteinase K. The purification procedure was carried
out with QIAmp spin columns; the DNA was adsorbed onto
the QIAmp silica membrane during a brief centrifugation step,
washed  twice,  and  eluted  with  200  μl  of  distilled  water.
Genomic DNA samples from all the members of the family
were screened for PAX6 gene mutation by direct sequencing.
All exons and flanking regions of PAX6 were amplified by a
polymerase chain reaction (PCR) using previously published
primer  sequences  (Table  1)  [13-15].  Briefly,  PCR
amplification  conditions  were:  Reaction  Mixture  Set  Up
(25 μl); 50 ng of genomic DNA, 10× PCR buffer, 1.5 mM
MgCl2, 0.2 mM dNTPs, 5 µmol each of sense and antisense
primers and 2.5U of Taq DNA polymerase (Sangon Biotech,
Shanghai, China). The cycling conditions for PCR were an
initial denaturation step at 95 °C for 5 min, 10 cycles of
touchdown PCR with 1 °C down per cycle from 60 °C to
50 °C, followed by 25 cycles with denaturation at 95 °C for
25 s, annealing at 55 °C for 25 s and extension at 72 °C for
40s, then finally extension at 72 °C for 10 min. PCR products
were  isolated  by  electrophoresis  on  2%  agarose  gels  and
sequenced using the BigDye Terminator Cycle sequencing kit
V  3.1  (ABI  Applied  Biosystems;  Sangon  Co.,  Shanghai,
China) on an ABI PRISM 3730 Sequence Analyzer (ABI),
according to the manufacturer’s instructions.
Computational  algorithms:  Protein  sequences  among  8
different species were aligned using ClusatalW. The three
Figure 1. Pedigree of the aniridia and
congenital  progressive  cataract.  It  is
inherited  as  an  autosomal  dominant
trait.  The  proband  is  marked  with  an
arrow.  Squares  and  circles  indicate
males and females respectively. Black
and  white  symbols  represent  affected
and  unaffected  individuals,
respectively.
TABLE 1. PCR PRIMERS AND PRODUCT SIZES OF THE PAX6 GENE.
Exon Sense primer (5′-3′) Antisense primer (5′-3′) Product size
(bp)
1 and 2 GCATGTTGCGGAGTGATTAG CTCCTGCGTGGAAACTTCTC 645
3 and 4 GGACTTAGGGTTTGATGACAG CCAGAAAGACCAGAGGCAC 644
5 TGAGGATGCATTGTGGTTGT GAAATGAAGAGAGGGCGTTG 373
6 CGTAAGCTTGTCATTGTTTAATGC AGAGAGGGTGGGAGGAGGTA 388
7 GGTTGTGGGTGAGCTGAGAT AAGCCCTGAGAGGAAATGGT 333
8 GGCTGTCGGGATATAATGCT CAAAGGGCCCTGGCTAAAT 355
9 AGGTGGGAACCAGTTTGATG TGGGACAGGTTAGCACTGTGT 385
10 and 11 AGCAGTGGAGGTGCCAAG TCTCAAGGGTGCAGACACAG 537
12 CAGACTTGTTGGCAGAGTTCC TAAACACGCCCTCCCATAAG 345
13 CATGTCTGTTTCTCAAAGGGA TTGTGTCCCCATAGTCACTGA 210
Molecular Vision 2012; 18:465-470 <http://www.molvis.org/molvis/v18/a50> © 2012 Molecular Vision
466diamensional structure of PAX6 paired domain was analyzed
using the PyMOL tool.
RESULTS
Clinical evaluation: We identified a three-generation family
with autosomal dominant aniridia and congenital progressive
cataract (Figure 2). According to classification of aniridia
phenotypes [16], all the six affected patients were categorized
into iris 6 (complete aniridia). The best corrected visual acuity
ranged from LP to 0.3. All of the affected patients were had
horizontal nystagmus except I:2. Corneal curvature ranged
from 35.2 to 43.0 (38.2±2.0 D in the minimal meridian and
40.8±2.2 D in the maximal meridian), and central corneal
thickness (CCT) measured in the clear corneas (II:2, II:5, III:
2 and III:4) ranged from 617 μm to 682 μm (642.5±24.4 μm).
The above data demonstrated flattened and thickened corneas
in the affected patients. Ectopia lentis was detected in patient
II:4, but not in patient III:2 or III:4. There was no family
history  of  other  systemic  abnormalities.  All  the  clinical
findings were summarized in Table 2.
Genetic analysis: By direct sequencing of the coding and
flanking  regions  of  PAX6,  a  heterozygous  mutation  (c.
307C>T)  was  detected  in  all  the  six  affected  individuals
(Figure 3). The mutation resulted in the substitution of an
arginine codon for a termination codon (p.R103X). The c.
307C>T  mutation  was  detected  neither  in  the  unaffected
members  of  the  family,  nor  in  any  of  the  200  control
chromosomes  that  were  analyzed  from  the  same  ethnic
background.
Computational analysis: The sequence alignment analysis
showed  that  the  Arg103  of  human  PAX6  protein  (Homo
sapiens,  NP_000271.1)  were  highly  conserved  in  various
species  including  Rattus  norvegicus  (NP_037133.1),  Bos
Taurus  (NP_001035735.1),  Macaca  mulatta
(XP_001085332.1),  Xenopus  (Silurana)  tropicalis
(NP_001006763.1),  Sus  scrofa  (NP_001231102.1),
Cricetulus  griseus  (XP_003497614.1),  and  Anolis
carolinensis (XP_003214735.1; Figure 4). PyMOL analysis
showed that the p.R103X mutation was located at the DNA-
binding domains of PAX6 (Figure 5) [17].
DISCUSSION
In the present study, we identified a recurrent mutation (c.
307C>T)  in  PAX6  in  a  three-generation  aniridia  and
congenital  progressive  cataract  family  of  Chinese  origin.
Although  the  c.307C>T  mutation  had  been  previously
reported,  it  was  associated  with  isolated  aniridia  or
anophthalmia when the patient had compound mutations, and
belonged to Caucasian population [18-20]. Our study first
identified of the PAX6 c.307C>T mutation in a large pedigree
Figure 3. Sequencing results of the PAX6 gene. A: The sequence of
an affected member (individual II:4) is shown. B: The sequence of
an unaffected member (II:3) is shown. A heterozygous mutation (c.
307C>T) is detected in the exon 6 of PAX6.
Figure 2. Slip lamp photographs of all the affected individuals. All the affected patients are had complete aniridia. The phenotypes are described
and summarized in Table 2.
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467with  aniridia  and  congenital  progressive  cataract.  In  this
family, a thickened CCT (642.5±24.4 μm) was detected as a
common clinical manifestation, which was consistent to the
previous  studies  (631.6±50.8  μm)  [21],  compared  to  the
measurement in healthy normal subjects (550.3±31.1 μm)
[ 22]. AAK including central cornea thickness, flat cornea,
corneal  panus,  and  corneal  vascularization  indicated  that
PAX6 had a crucial role not only in iris but also in corneal
development. Broad phenotypic variability was observed in
nystagmus,  ptosis,  strabismus,  glaucoma,  corneal  pannus,
corneal curvature, corneal vascularization, cataract subtype,
ectopia lentis, axial length, and optic disc anomalies, showing
phenotyically heterogeneous manifestations of the PAX6 c.
307C>T mutation.
Human  PAX6  is  composed  of  two  DNA-binding
domains: the paired domain (PD) of 128 amino acids and the
homeodomain (HD) of 61 amino acids separated by a linker
region of 79 amino acids, and is followed by a proline, serine,
threonine-rich (PST) domain of 79 amino acids that have
transcriptional trans-activation function [22]. It is a highly
TABLE 2. THE CLINICAL FEATURES OF ANIRIDIA PATIENTS IN THE CHINESE FAMILY.
Patient I:2 II:2 II:4 III:1 III:2 III:4
Gender F F M M F F
Age (years) 63 43 38 20 11 11
BCVA R/L LP/HM 0.25/HM 0.06/0.02 LP/LP 0.3/0.2 0.02/0.06
Nystagmus NO YES YES YES YES YES
Ptosis YES YES NO NO NO NO
Strabismus Exotropia Exotropia NO Exotropia NO Exotropia
Glaucoma NA YES YES YES NO NO
Corneal pannus YES NO NO YES NO NO
CCT R/L (μm) NA 617/628 622/628 NA 671/682 634/658
Corneal curvature (D) Min:37.5
Max:38.4
Min:35.2
Max:42.5
Min:39.9
Max:41.5
NA Min:38.0
Max:38.4
Min:40.2
Max:43.0
CV YES NO NO YES NO NO
ECD (/mm3) NA 1798 3333 NA NA NA
ACD R (mm) 2.37 3.25 2.07 NA NA 2.14
Lens Total
Cataract
IOL Nuclear
cataracts
Aphakia PSC PSC
EL NA NA YES NA NO NO
Iris Complete
aniridia
Complete
aniridia
Complete
aniridia
Complete
aniridia
Complete
aniridia
Complete
aniridia
C/D R/L NA 0.8/0.4 NA 0.9/0.9 0.3/0.3 0.5/0.5
MT R/L (μm) NA 216 NA NA NA NA
AL R/L (mm) 25.0/26.6 NA NA 25.4/25.0 21.4/21.2 19.7/19.7
CNS defect NO NO NO NO NO NO
        Abbreviations: F, Female; M, Male; BCVA, Best-Correct Visual Acuity; R, Right eye; L, Left eye; LP, Light Perception; HM,
        Hand Motion; NA, Not Available; CCT, Central Corneal Thickness; CV, Corneal Vascularization; ECD, Endothelial Cell
        Density; ACD, Anterior Chamber Depth; IOL, Intraocular Lens; PSC, Posterior Subcapsular Cataracts; EL, Ectopia Lentis; C/
        D, Cup-to-disk Ratio; MT, Macular Thickness; AL, Axial Length; CNS, Central Nervous System.
Figure 4. Multiple-sequence alignment
in  PAX6  from  8  different  species.  It
demonstrates  that  R103  is  highly
conserved (highlighted in red).
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468conserved  transcription  factor  which  regulates  the  tissue-
speciﬁc  expression  of  various  molecules,  hormones,  and
structural proteins. It is required for the development of the
nervous  system,  eyes,  nose,  pancreas,  and  pituitary  gland
[23-26]. The sequence alignment analysis shows that Arg103
is  highly  conserved  in  vertebrates.  Thus  the  c.307C>T
mutation affecting the PD is inclined to be pathogenic and lead
to congenital anomalies in eye development.
Nonsense-mediated  decay  (NMD)  is  the  process  by
which  mRNAs  containing  pre-mature  termination  codons
(PTCs) are degraded before production of supposed truncated
proteins [27,28]. It is reported that if a PTC is located 50–55
nucleotides 5′ to the last exon-exon junction, it is considered
premature, and the mRNA is targeted for rapid decay [29].
Therefore, the PAX6 c.307C>T mutation, occurring in exon 6
further upstream the last exon-exon junction, is supposed to
result  in  NMD  instead  of  truncated  protein.  Therefore,  it
probably behaves as loss-of-function mutants as predicted by
haploinsufficiency [30]. Further investigation is still required
Figure 5. Stuctural modeling of the PAX6 paired domain. Cylinders
and  arrows  represent  α  helices  and  β  strands,  respectively.  The
orange double helix in the center denotes DNA. The red segment
represents  the  mutation  point  (R103).  The  structural  model  by
PyMOL  analysis  shows  the  relationship  between  PAX6  paired
domain and DNA.
to  elucidate  why  the  same  non-sense  mutation  results  in
variation of phenotypes.
In conclusion, we detect a PAX6 c.307C>T mutation in
an aniridia and congenital progressive cataract family, and
summarize the variable phenotypes among the patients. Our
findings  expand  the  phenotypic  spectrum  of  aniridia  in  a
different ethnic background.
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